Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients - APAP study

Sint Antonius Ziekenhuis0 个研究点目标入组 28 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Inclusion criteria for morbidly obese patients:
•- BMI > 40 kg/m2 undergoing bariatric surgery.
•- 18 -60 years old
•- ASA physical classification of II or III
•- All racial and ethnic groups will be included;Inclusion criteria for normal weight patients:
•- BMI between 18 and 25 kg/m2 undergoing general surgery
•- 18 -60 years old
•- ASA physical classification of I, II or III
•- All racial and ethnic groups will be included

•Exclusion criteria for all patient groups:
•- Renal insufficiency identified by GFR < 60 ml/min/1.73m2
•- Liver disease identified by liver function tests: ASAT, ALAT, prothrombin time, *-GT, bilirubin, creatinine, albumin and alkaline phosphatase (ALP) ( > 3 times upper limit of normal values)
•- Patients with Gilbert-Meulengracht syndrome
•- Chronic alcohol intake or use of alcohol within last 72 hours
•- Pregnancy or breastfeeding
•- Patients who are treated with drugs know to affect CYP2E1 (inhibition: dithiocarb and disulfiram. Induction: isoniazid) and UGT (UDP-glucuronyltransferases) (induction: estradiol-containing contraceptives, carbamazepine, phenobarbital, phenytoin, mesuximide, oxcarbazepine, rifampicin, primidone, atazanavir / ritonavir, lopinavir / ritonavir, olanzapine, retigabine , nevaripine, efavirenz, saquinavir, nelfinavir, lamotrigine, felbamate, zonisamide, bupropion. Inhibition: valproic acid)
•- Diabetes mellitus type II patients
•- Acetaminophen intake before the study (24 hours before study)

发起方